Graf Acquisition Corp. IV
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- James A. Graf
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 1790 Hughes Landing Boulevard The Woodlands TX United States of America 77380
- IPO Date
- Jul 13, 2021
- CIK
- 0001845459
- Website
- grafacq.com
- Similar Companies
- Business
- Graf Acquisition Corp. IV (NYSE: GFOR) operates as a blank check company, or special purpose acquisition company (SPAC), with no significant independent operations; it focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, primarily targeting opportunities in industrial, technology, healthcare, and biotechnology sectors. Incorporated in 2021 and headquartered in The Woodlands, Texas, the company completed its initial public offering in May 2021, raising $150 million (upsized to $171.6 million upon full exercise of the over-allotment option), with proceeds held in trust to fund a potential de-SPAC transaction; each unit comprised one share of Class A common stock and one-fifth of a redeemable warrant exercisable at $11.50 per whole share. Graf targets businesses across diverse industries, leveraging its management team's expertise led by CEO James A. Graf, without specified geographic limitations beyond its U.S. base. In September 2023, Graf completed a reverse merger business combination with NKGen Biotech, Inc., a clinical-stage biotechnology firm developing natural killer (NK) cell therapies for neurodegenerative diseases and cancer, including lead candidates SNK01 (autologous NK cells) and SNK02 (allogeneic NK cells); post-merger, the combined entity operates as NKGen Biotech, Inc., with its common stock and warrants trading under new ticker symbols NKGN and NKGNW, initially on Nasdaq before delisting to OTC markets amid compliance challenges. Subsequent developments include NKGen's full acquisition of NKMax Co., Ltd. in September 2025, securing control over global NK cell manufacturing, intellectual property, and supply chain assets previously strained by NKMax's bankruptcy; this followed NKGen's Nasdaq delisting in July 2025 due to market value deficiencies, new funding from AlpineBrook Capital to support clinical programs through Phase II trials, and strategic partnerships such as with HekaBio K.K. for troculeucel development in Japan. The company maintains license agreements with NKMax for its NK platform and continues advancing pipeline assets without approved commercial products or reported revenue as of late 2025.
Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 25, 2023
Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 20, 2023
Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 13, 2023
Graf Acquisition Corp. IV Announces Intent to Adjourn Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 8, 2023
NKGen Biotech, Inc. Announces First Patient Dosed in Phase I Clinical Trial of SNK02, Allogeneic NK Cell Therapy Product Candidate, for the Treatment of Solid Tumors
Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Effectiveness of Form S-4 for Proposed Business Combination
Graf Acquisition Corp. IV Currently Has Proxies from More Than 65% of its Stockholders to Approve Extension
Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Letter of Intent for a Business Combination
Graf Acquisition Corp. IV Withdraws Extension Proposal
Graf Acquisition Corp. IV Announces the Separate Trading of its Common Stock and Warrants, Commencing July 12, 2021
Graf Acquisition Corp. IV Announces Closing of Underwriters' Over-Allotment Option in Connection with its Initial Public Offering
Graf Acquisition Corp. IV Announces Closing of Underwriters’ Over-Allotment Option in Connection with its Initial Public Offering
Graf Acquisition Corp. IV Announces Closing of $150 Million Initial Public Offering